Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + XELOX in resectable colorectal liver metastases: radiologic, morphologic, and pathologic response correlation study
2011-000143-24Phase 4Completed
- Sponsor
- GEMCAD
- Start
- Jan 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bevacizumab, capecitabine and oxaliplatin in colorectal cancer (CRC), sponsored by GEMCAD. Primary endpoints: Objective response rate according to RECIST v1.1, Morphologic response rate by CT and 1 more. Started Jan 2012; status: completed.
02
Drugs
bevacizumabcapecitabineoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-000143-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000143-24.